12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

HyperAcute Pancreas: Phase III started

NewLink began an open-label Phase III trial to compare HyperAcute Pancreas plus standard of care (SOC; 5-fluorouracil (5-FU), leucovorin, irinotecan and oxaliplatin) vs. SOC alone in about...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >